Table 1 Baseline characteristics of 511 Caribbean Hispanic participants in the study cohort

Variables	All Patients (n = 511)						Controls (n = 399)						Cases (n = 112)						p-value ^d
Variables	mean	SD	SE^M	Min	Max	median	mean	SD	SE^M	Min	Max	median	mean	SD	SE^M	Min	Max	median	p-value ^d
Age (years)	68.01	10.95	0.51	27.00	94.00	66.00	67.72	11.1	0.59	27.0	94.00	66.00	69.02	10.44	1.03	37.00	89.00	79.00	0.322
BMI (kg/m²)	28.40	5.71	0.27	11.48	52.67	27.46	27.89	5.3	0.28	11.48	47.02	25.82	30.15	6.73	0.67	15.95	52.67	29.41	0.002
AMR	0.115	0.04	0.002	0.01	0.56	0.12	0.11	0.04	0.002	0.01	0.56	0.12	0.11	0.03	0.003	0.02	0.19	0.12	0.370
IBS	0.680	0.13	0.006	0.16	0.96	0.77	0.70	0.13	0.007	0.23	0.96	0.77	0.70	0.13	0.01	0.16	0.93	0.77	0.821
YRI	0.205	0.14	0.006	0.004	0.83	0.11	0.20	0.14	0.007	0.004	0.72	0.34	0.19	0.14	0.01	0.03	0.83	0.11	0.606
	N			%			N			%			N			%
Type 2 Diabetes Mellitus	280			54.78			209			52.38			71			63.39			0.034
Hypertension	428			83.75			330			82.71			98			87.50			0.190
Dyslipidemias	367			71.82			286			71.68			81			72.32			0.894
Smoking	69			13.50			60			15.04			9			8.03			0.025
MACCEs^a	42			8.22			32			8.02			10			8.93			0.763
Non-fatal MI^a	19			3.72			16			4.01			3			2.68			0.464
Stent Thrombosis^a	15			2.93			12			3.01			3			2.68			0.850
Ischemic Strokes /TIA^a	14			2.74			11			2.76			2			1.78			0.512
CV Deaths^a	4			0.78			3			0.75			1			0.89			0.887
Bleedings Events^b	83			16.24			67			16.79			16			14.29			0.518
Aspirin Use	323			63.21			251			62.91			72			64.29			0.830
Statins Use	404			79.06			323			80.95			81			72.32			0.160
CCB	156			30.53			122			30.58			34			30.36			0.751
PPI	123			24.07			82			20.55			41			36.61			0.913
LVEF ≤ 40%	42			8.22			33			8.27			9			8.04			0.991
ACS & Stable CAD	371			72.60			295			73.93			76			67.86			0.120
Coronary Artery Stenting^c	191			37.38			159			39.85			32			28.57			0.495
PAD	123			24.07			94			23.56			29			25.89			0.378
Sex (Males)	282			55.18			237			59.40			45			40.18			< 0.001

BMI means body mass index. IBS, AMR, and YRI stand for Iberians (European), Native American, and Yoruba (African) ancestries, respectively. Significance differences between cases (PRU ≥ 230, n = 112) and controls (PRU < 230, n = 399) were statistically tested by either two-tailed, unpaired t-tests for independent samples (continuous variables) or the two proportions z-tests (nominal variables, %). Due to rounding errors, percentages may not equal 100%.
^aMACCEs: major adverse cardiovascular and cerebrovascular events after 6 months of follow-up, as described elsewhere³⁵.
^bBleeding events is a combination of major and minor events.
^cAll patients with ACS and some with stable CAD underwent PCI (i.e., percutaneous coronary interventions with stent deployment). MI myocardial infarctions (i.e., STEMI and NSTEMI). TIA transient ischemic attack. CCB calcium channel blockers. PPI proton pump inhibitors. LVEF left ventricular ejection fraction. PAD peripheral artery disease.
^dAlternatively, two-tailed Mann-Whitney U tests for continuous variables were done when normality assumption was violated.

Search